206 related articles for article (PubMed ID: 24403505)
21. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.
Ali BH
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):272-9. PubMed ID: 20050845
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo.
Ip V; Liu JJ; McKeage MJ
Clin Exp Pharmacol Physiol; 2013 Jun; 40(6):371-8. PubMed ID: 23556474
[TBL] [Abstract][Full Text] [Related]
23. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.
Liu JJ; Lu J; McKeage MJ
Curr Cancer Drug Targets; 2012 Oct; 12(8):962-86. PubMed ID: 22794121
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity.
McDonald ES; Randon KR; Knight A; Windebank AJ
Neurobiol Dis; 2005 Mar; 18(2):305-13. PubMed ID: 15686959
[TBL] [Abstract][Full Text] [Related]
25. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.
Bianchi R; Brines M; Lauria G; Savino C; Gilardini A; Nicolini G; Rodriguez-Menendez V; Oggioni N; Canta A; Penza P; Lombardi R; Minoia C; Ronchi A; Cerami A; Ghezzi P; Cavaletti G
Clin Cancer Res; 2006 Apr; 12(8):2607-12. PubMed ID: 16638873
[TBL] [Abstract][Full Text] [Related]
26. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.
Jamieson SM; Liu JJ; Connor B; Dragunow M; McKeage MJ
Neurotoxicology; 2007 Nov; 28(6):1092-8. PubMed ID: 17686523
[TBL] [Abstract][Full Text] [Related]
27. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum.
Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G
Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
29. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
[No Abstract] [Full Text] [Related]
30. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Expert Opin Drug Saf; 2004 Nov; 3(6):535-46. PubMed ID: 15500413
[TBL] [Abstract][Full Text] [Related]
32. New data question treatment for oxaliplatin neurotoxicity.
Wolf SL
Clin J Oncol Nurs; 2008 Feb; 12(1):14; author reply 14. PubMed ID: 18323035
[No Abstract] [Full Text] [Related]
33. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies.
Calls A; Carozzi V; Navarro X; Monza L; Bruna J
Exp Neurol; 2020 Mar; 325():113141. PubMed ID: 31865195
[TBL] [Abstract][Full Text] [Related]
35. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
36. Neurotoxicity of cancer chemotherapy.
Dropcho EJ
Semin Neurol; 2010 Jul; 30(3):273-86. PubMed ID: 20577934
[TBL] [Abstract][Full Text] [Related]
37. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.
Carozzi VA; Canta A; Oggioni N; Sala B; Chiorazzi A; Meregalli C; Bossi M; Marmiroli P; Cavaletti G
Exp Neurol; 2010 Dec; 226(2):301-9. PubMed ID: 20832406
[TBL] [Abstract][Full Text] [Related]
38. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Curr Opin Neurol; 2015 Oct; 28(5):500-7. PubMed ID: 26197027
[TBL] [Abstract][Full Text] [Related]
40. [Chemotherapeutic neurotoxicity].
Lebrun C; Frenay M
Rev Neurol (Paris); 2003 Sep; 159(8-9):741-54. PubMed ID: 13679716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
